The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology/Oncology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Tue, 11 Aug 2026 10:16:39 GMT 2026 NEJM Group en-us 1440 A 55-year-old man with a smoking history of 10 pack-years presented with 2 years of an enlarging, painless lump below his right ear. A previously unnoticed smaller mass in the left parotid gland was seen on examination. https://www.nejm.org/doi/full/10.1056/NEJMicm2604482?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2604482 Xiaoling Pan, Cheng Lin 2026-08-08 Warthin Tumors In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2603878?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603878 Mary-Ellen Taplin, Martin Gleave, Neal D. Shore, Angela Lopez-Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Paul L. Nguyen, Ronaldo Damião, Toshiyuki Kamoto, Ashley Ross, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Álvaro Juárez Soto, Huihui Ye, Geoffrey Gotto, Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Branko Miladinovic, Sharon A. McCarthy, Christopher P. Evans, Adam S. Kibel, the PROTEUS Investigators* 2026-08-06 Perioperative Apalutamide in High-Risk Localized Prostate Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... https://www.nejm.org/doi/full/10.1056/NEJMe2606250?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606250 Emmanuel S. Antonarakis 2026-08-06 A Watershed Moment in the Perioperative Treatment of Prostate Cancer A 60-year-old woman with stage II triple-negative breast cancer presented to the ED with a weeklong history of fevers, rigors, malaise, nonproductive cough, and nausea. https://www.nejm.org/doi/full/10.1056/NEJMcps2516922?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcps2516922 Hae Lin Cho, Nancy Berliner, Stephen Babcock, Yee-Ping Sun, Bruce Levy 2026-08-06 Consumed with Inflammation In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. https://www.nejm.org/doi/full/10.1056/NEJMoa2604126?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604126 Neeraj Agarwal, Nobuaki Matsubara, Arun A. Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D. Shore, Timuçin Çil, Christof Vulsteke, Hsiao-Jen Chung, Stefanie Zschäbitz, A. Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim Fizazi 2026-07-30 PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. https://www.nejm.org/doi/full/10.1056/NEJMoa2603870?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603870 Cyrille Touzeau, Roberto Mina, Hang Quach, Vania Hungria, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra Chaulagain, Meletios Athanasios Dimopoulos, Nizar J. Bahlis, Senem Maral, Niels W.C.J. van de Donk, Jayr Schmidt Filho, Khalid Saja, Raphael Teipel, Miki Ando, Wilfried Roeloffzen, Ombretta Annibali, Bradley Augustson, Cirino Botta, Michel Delforge, Emmanuelle Bourgeois, Gabriele Buda, Marek Hus, Aurore Perrot, Meir Preis, Meral Beksac, Ludek Pour, Sarah Farmer, Marta Nunes, Albert Oriol, Thomas Melchardt, Yu Hu, Max Flogegård, Dai Wang, Lixia Pei, Susan Wroblewski, Ingrid M. Ariës, Natalia A. Quijano Cardé, Tatiana Perova, Tertia de Jager, Tzu-Min Yeh, Veronique Vanquickelberghe, Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, Ola Landgren, the MajesTEC-9 Trial Investigators* 2026-07-30 Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies. https://www.nejm.org/doi/full/10.1056/NEJMra2502459?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2502459 Theodore E. Warkentin, Andreas Greinacher 2026-07-30 Platelet-Activating Anti–Platelet Factor 4 Disorders The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated... https://www.nejm.org/doi/full/10.1056/NEJMe2605582?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605582 Rana R. McKay 2026-07-30 Precision Intensification in Metastatic Prostate Cancer The treatment landscape of multiple myeloma has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology, refined patient stratification, the integration of new prognostic biomarkers, and sustained therapeutic innovation. Today, most patients receive proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies as frontline... https://www.nejm.org/doi/full/10.1056/NEJMe2605404?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605404 María-Victoria Mateos 2026-07-30 Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules This study supports enzymatic cross-correction of neurons and oligodendrocytes by atidarsagene autotemcel, a gene therapy that prevents or slows neurodegeneration in children with early-onset metachromatic leukodystrophy. https://www.nejm.org/doi/full/10.1056/NEJMc2505002?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2505002 Vasco Meneghini, Valeria Calbi, Filippo Casalini, Elisabeth Mangiameli, Francesco Morena, Marco Piccoli, Ilaria Laface, Ilaria Rossomanno, Francesca Ornaghi, Andrea Ghiroldi, Paola M.V. Rancoita, Francesca Fumagalli, Sabata Martino, Luigi Anastasia, Luigi Naldini, Alessandro Aiuti, Angela Gritti 2026-07-30 Cross-Correction in HSC Gene Therapy for Metachromatic Leukodystrophy Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. https://www.nejm.org/doi/full/10.1056/NEJMoa2601486?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601486 Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, Albert Font, Tudor Ciuleanu, Jonathan Chatzkel, Takuya Koie, Christopher J. Hoimes, Javier Puente, Yousef Zakharia, Eli Rosenbaum, Katharina Boehm, Yohann Loriot, Jens Bedke, Thomas B. Powles, Andrea Necchi, Pawel Wiechno, Carlos Álvarez-Fernández, Tae-Hwan Kim, Niara Oliveira, Thomas W. Flaig, Heidi S. Wirtz, Michael Mihm, Qinlei Huang, Aljosja Rogiers, Blanca Homet Moreno, Alfonso Gómez de Liaño, the KEYNOTE-B15/EV-304 Investigators* 2026-07-23 Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin, the RASolute 302 Trial Investigators* 2026-07-23 Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer In the ICU, a resident is surrounded by deaths, each one leaving him with a sense of emptiness. Then a Christmas tragedy highlights medicine’s privilege of bearing witness to love as well as death. https://www.nejm.org/doi/full/10.1056/NEJMp2516818?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2516818 Tristan Jones 2026-07-23 Love and Death For decades, pancreatic ductal adenocarcinoma (PDAC) has been perhaps the clearest example of a cancer that is driven by a dominant oncogenic event yet is resistant to therapeutic exploitation. More than 90% of pancreatic cancers harbor activating RAS mutations, most commonly those involving KRAS codon 12,... https://www.nejm.org/doi/full/10.1056/NEJMe2606948?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606948 Shivan Sivakumar 2026-07-23 Breaking the RAS Barrier in Pancreatic Cancer For more than two decades, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been the standard of care for muscle-invasive bladder cancer. Despite this approach, relapse rates have remained high and long-term survival gains have been modest. The treatment landscape began to shift with the NIAGARA trial, which showed a... https://www.nejm.org/doi/full/10.1056/NEJMe2605872?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605872 Srikala S. Sridhar 2026-07-23 A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2600157?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S. Vincent Rajkumar 2026-07-16 Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma Multiple myeloma has undergone a therapeutic revolution at a pace nearly unmatched in oncology. Yet amid these advances, a key assumption in multiple myeloma therapy persists: more and longer treatment is better. The trial by Kumar and colleagues (ENDURANCE), reported in this issue of the Journal,1 ... https://www.nejm.org/doi/full/10.1056/NEJMe2604761?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2604761 Hira Mian, Luciano J. Costa 2026-07-16 Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma After total hip or knee arthroplasty, aspirin alone was noninferior to rivaroxaban followed by aspirin in preventing symptomatic venous thromboembolism, with a similarly low risk of bleeding complications. https://www.nejm.org/doi/full/10.1056/NEJMoa2603649?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 Sudeep Shivakumar, Davide Matino, David Zukor, Susan R. Kahn, George Vincent, Raman Mundi, Pascal-Andre Vendittoli, Mohammad Refaei, Eric Bohm, Michael Tanzer, Stéphane Pelet, Glen Richardson, James Powell, Rick Ikesaka, James Douketis, Sarah Ward, Paul Kim, Stephen Mann, Susan Pleasance, Jocelyn Cormier, Pantelis Andreou, Kara Matheson, Chris Theriault, Carol West, David Anderson, Peter L. Gross, the EPCAT III Trial Investigators* 2026-07-12 Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. https://www.nejm.org/doi/full/10.1056/NEJMc2604408?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2604408 Per-Ola Carlsson, Xiaomeng Hu, Hanne Scholz, Torbjörn Lundgren, Sofie Ingvast, Tim Scholz, Olof Eriksson, Per Liss, Irina Velikyan, Di Yu, Grigol Tediashvili, Tobias Deuse, Olle Korsgren, Sonja Schrepfer 2026-07-10 Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. https://www.nejm.org/doi/full/10.1056/NEJMoa2518990?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2518990 Dongsheng Yue, Meijuan Huang, Pingping Song, Yuejun Chen, Bin Li, Junke Fu, Jianji Guo, Chao Cheng, Qixun Chen, Shidong Xu, Hongxu Liu, Fang Lv, Jian Hu, Ke Jiang, Weimin Mao, Bo Shen, Feng Ye, Jie Li, Xueying Zhang, Shiping Guo, Bentong Yu, Yuming Zhu, Ming Wu, Wei Zheng, Fang Chen, Zhengfu He, Yuansong Bai, Hua Xin, Keneng Chen, Naiquan Mao, Yu Zhang, Bo Wang, Lei Zhang, Xingwu Chen, Xinyu Mei, Liyun Miao, Runjie Wang, Gaofeng Li, Juntao Yao, Jun Zhao, Chun Chen, Junfeng Liu, Li Wei, Xiaolong Yan, Bo Jin, Xianling Liu, Zhidong Liu, Hui Tian, Wenqun Xing, Lin Yang, Di Ge, Xiangnan Li, Shanqing Li, Yongxiang Song, Aimin Zang, Dahai Zhang, Wu Zhuang, Zijin Liu, Xiaobin Yuan, Tao Fu, Zhilin Shen, Xiaojun Zhang, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding, You Lu, Changli Wang, the ELEVATE Study Group* 2026-07-09 Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer